Law firm Bragar Eagel & Squire announced an investigation into Veritone, Inc. on behalf of stockholders, signaling potential legal risks and adding to a recent string of shareholder actions against publicly traded companies. The firm encourages investors who have suffered losses to come forward.
Bragar Eagel & Squire, a national law firm, has initiated an investigation into Veritone, Inc. (VERI) on behalf of the company's stockholders, according to a press release dated April 22, 2026.
"Bragar Eagel & Squire, P.C. encourages investors who have suffered losses in Veritone (VERI) to contact him directly to discuss their options," Litigation Partner Brandon Walker said in a statement.
The investigation focuses on potential violations of federal securities laws and seeks to recover financial losses for Veritone investors. The firm's announcement did not specify a class period or the exact nature of the alleged misconduct.
The announcement of a shareholder investigation often precedes a formal class-action lawsuit, which can lead to significant legal costs and damage investor confidence. Veritone shares, which trade on the Nasdaq, could face increased volatility as the market digests the potential for litigation.
The move by Bragar Eagel & Squire is the latest in a series of shareholder-focused legal actions against technology and biotech companies. Recently, Hagens Berman filed a class action against Soleno Therapeutics (SLNO), alleging the company concealed safety risks, which resulted in a 27% single-day stock drop after corrective disclosures.
Similarly, ImmunityBio (IBRX) saw its stock fall 21% after the FDA issued a warning letter regarding "false or misleading" promotional claims, leading to a securities fraud lawsuit filed by Levi & Korsinsky.
These cases highlight the risks companies face when making public statements, whether about product efficacy, as in the ImmunityBio case, or corporate strategy. Gemini Space Station (GEMI) faced a lawsuit alleging its IPO documents concealed an impending "corporate pivot," which caused the stock to fall over 75% from its IPO price.
For Veritone investors, the investigation introduces a new layer of risk and uncertainty. The next major catalyst will be whether the investigation leads to a formal class-action lawsuit filing, which would likely have a material impact on the stock price.
This article is for informational purposes only and does not constitute investment advice.
